On 11 February, Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), announced that the first patient has been enrolled in a clinical study evaluating Lymphoseek® (technetium Tc 99m tilmanocept) injection in women with known cervical cancer. The study, funded by a Fast-track grant from the National Institutes of Health (NIH), National Cancer Institute (NCI; 1R44CA180390-01) will assess the use of Lymphoseek in sentinel lymph node biopsy (SLNB) during cervical cancer surgery in support of the existing Lymphoseek label in lymphatic mapping. Lymphoseek is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.
Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) belongs to Healthcare sector. Its weekly performance is -0.61%. On last trading day company shares ended up at $0.98. Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) distance from 50-day simple moving average (SMA50) is -10.00%.
Avinger, Inc., (NASDAQ:AVGR) announced that it will release its financial results for the fourth quarter and year-end 2015 after the close of trading on Tuesday, March 1, 2016.
Avinger, Inc. (NASDAQ:AVGR) shares increased 5.93% in last trading session and ended the day at $16.62. AVGR Gross Margin is 43.10% and its return on assets is -74.40%. Avinger, Inc. (NASDAQ:AVGR) quarterly performance is -5.14%.
Corrections Corporation of America (NYSE:CXW) announced that its Board of Directors declared a quarterly dividend of $0.54 per share to be paid on April 15, 2016 to shareholders of record as of the close of business on April 1, 2016.
On 25 February, Corrections Corporation of America (NYSE:CXW) shares increased 2.19% and was closed at $29.38. CXW EPS growth in last 5 year was 5.20%. Corrections Corporation of America (NYSE:CXW) year to date (YTD) performance is 10.91%.
Repligen Corporation (NASDAQ:RGEN) reported Product revenue for the fourth quarter of 2015 increased to $21.4 million compared to $15.4 million for the fourth quarter of 2014, a year-over-year gain of 45% at constant currency or 39% as recorded (GAAP). Product gross profit for the fourth quarter of 2015 was $11.3 million, a year-over-year increase of $4.0 million or 55%.
Repligen Corporation (NASDAQ:RGEN) ended the last trading day at $25.78. Company weekly volatility is calculated as 5.34% and price to cash ratio as 12.33. Repligen Corporation (NASDAQ:RGEN) showed a weekly performance of 6.09%.
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by CTI BioPharma Corp. (NASDAQ: CTIC). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
CTI BioPharma Corp. (NASDAQ:CTIC) shares fell -4.83% in last trading session and ended the day at $0.63. CTIC Gross Margin is 88.20% and its return on assets is -142.60%. CTI BioPharma Corp. (NASDAQ:CTIC) quarterly performance is -47.11%.